Evommune
Palo Alto, United States · Biotechnology, Health Care · 45 employees
Evommune, Inc. is a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases. The company is creating game-changing science with the goal of delivering therapies that address symptoms and halt progressive disease.
Funding history
- Funding Round — $115.5M — Jan 2025
- Funding Round — $81.8M — Jan 2025
- Funding Round — $57.5M — Jan 2025
- Funding Round — $12.5M — Jan 2025
- Series series c — $115.0M — Oct 2024
Recent signals
- Feb 10, 2026: SEC 8-K (7.01): On February 10, 2026, Evommune, Inc. issued a press release announcing positive top-line data from its Phase 2a proof-of-concept trial of EVO301 for treating moderate-to-severe atopic dermatitis. The company will host a webcast to discuss these results, making it a significant event for stakeholders. This presentation will provide insights into the trial outcomes and their implications for ongoing development and potential market impact of EVO301. The event aligns with the company’s commitment to transparency and informing investors about significant advancements in their clinical pipeline.
- Jan 08, 2025: Raised $115.5M
- Jan 08, 2025: Raised $81.8M
- Jan 08, 2025: Raised $57.5M
- Jan 07, 2025: Raised $12.5M
- Oct 31, 2024: Raised $115.0M in Series series c
- Jun 28, 2023: Raised funding in Series series b
- Apr 26, 2023: Raised $50.0M in Series series b
See plans & pricing → Track Evommune’s funding, hiring, and signals — with verified contacts — on Fundz.